Cannabis is legal across 35 states (including Washington DC) in America. While federal legalisation has not yet happened – big pharmaceutical companies already fear that day.
Osagie Imasogie is the founder and chairman of Pennsylvania-based Ilera Healthcare, which is merging with Zelda Therapeutics (ASX:ZLD) to form Zelira Therapeutics. The move is to be voted on today at the latter company’s AGM.
Yesterday he told a broker lunch when cannabis was legalised federally in the US, big pharmaceuticals had a lot to lose.
“There is a $[US]330 billion ($486.4 billion) annual drug spend in the US. This year $US4.86 billion of that has switched from traditional pharmaceuticals to cannabis based drugs,” he said.
“It’s not a theoretical debate as to whether or not we’ll take market share – it has already happened.
“And 90 per cent of people who switched from a traditional product to a cannabis product said it was better than the original.”
You could have ordinary gravy, or cannabis gravy. Kiva Confections has created the latter although it’s currently only available in California.
Kiva has promised would-be customers it can take effect within 15 minutes, and its perfect for restoring a good mood after awkward conversations. If you’ve missed the boat, it will be releasing cannabis-based cocoa in time for Christmas.
This week’s biggest jumper was MMJ Group (ASX:MMJ). It owns 26 per cent of Canada-listed cannabis play Harvest One which released its financial results on Tuesday.
It made $4.1m in revenue in the September quarter – 142 per cent higher than the same quarter last year.
MGC Pharmaceuticals (ASX:MXC)is now pushing into Latin America. It is launching a joint venture with BrasilInvest Group to distribute its products into Brazil.
The Latin American market is estimated to reach $US8.5 billion by 2028.
Australian Primary Hemp (ASX:APH) signed a collaboration MOU with Mycelium Biotech Services (MBS). The two firms will develop new products with the benefits of APH’s hemp and MBS’ mushroom-filled protein power.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.